MedCity News April 12, 2024
Torl BioTherapeutics’ $158 million Series B-2 financing will finance clinical testing of its pipeline of antibody drug conjugates in development for various types of cancer. Neuroscience and immunology are among the therapeutic areas represented in our roundup of other recent biotech financings.
The class of cancer therapies called antibody drug conjugates, or ADCs, continues to be an area of strong investor interest and Torl BioTherapeutics is the latest biotech to capitalize on it. This week, Torl unveiled $158 million in financing, the same sum it raised when launched last year.
Los Angeles-based Torl calls the new capital a Series B-2 financing. The proceeds will support continued clinical development of its lead program, TORL-1-23. This ADC targets tumors that express a...
Today's Sponsors
Today's Sponsor